Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Nucleic acids – a biomedical revolution
- Nucleic acids as therapeutics
- Nucleic acid delivery systems
- Block copolymer micelles
- Nucleosome-mimicking polymer particles
- Cationic nanoparticles transfect cells
- Why does it work, and how can one improve?
- Variation of cSCK shell composition
- Modulating binding affinity/buffering capacity
- Improved transfection efficiency
- Oligonucleotide delivery with cSCKs
- Delivery peptide nucleic acids (PNAs)
- Arrangement of the nucleic acids
- High density spherical nucleic acids
- Conjugates are taken up by cells
- Enter all cell lines and primary cells studied
- Targeting cancer cells by antibodies
- Nucleic acids as transfection agent
- Novel chemistry for hollow particle synthesis
- TEM of nanopods
- Hollow spherical nucleic acids (hSNAs)
- hSNA properties
- hSNAs have sharp melting transitions
- hSNA slow down nuclease degradation
- hSNAs enter cells in high quantities
- Gene regulation control using hSNAs
- Acknowledgement
Topics Covered
- Using nucleic acids as therapeutics
- Nucleic acid delivery systems
- Nucleosome mimicking polymer particles
- Cationic shell-crosslinked knedel-like nanoparticles (cSCKs)
- High density spherical nucleic acids (SNAs)
- Hollow SNAs
Links
Series:
Categories:
Talk Citation
Zhang, K. (2015, May 4). Nanotechnology for intracellular nucleic acid delivery [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/EXFM2690.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Ke Zhang has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Nanomedicine
Transcript
Please wait while the transcript is being prepared...
0:00
It's a great pleasure for me
to be one of the speakers
for the Henry Stewart Talks.
The title of my talk is,
Nanotechnology for Intracellular
Nucleic Acid Delivery.
0:12
Nucleic acids have become an
indispensable research tool.
And we can certainly say that.
They have revolutionized
biomedical research.
From a pharmaceutical
development point of view,
they are at present mostly
used for diagnostics
and detection applications.
Applications such as
PCR, DNA microarrays
and these bio-barcode assays
can be used to accurately detect
biomarkers that can be
used to provide insights
into disease processes
and pinpoint pathways
where treatments may interfere.
What's perhaps even more exciting
about nucleic acids in my opinion
are their potential as therapeutics.
One reason for this is that in
principle, one change in disease
target would only require a change
in the nucleic acid sequence itself.
So you can imagine that once
a successful formulation
of nucleic acid
therapeutics is developed,
subsequent formulations will
follow much more easily.
And this will likely
bypass many of the steps
involved in the development of a
traditional small molecule drug.
Because of the versatility
and programmability
of synthetic nucleic acids,
there is a significant amount
of hope and promise in developing
nucleic acid therapeutics.
And this has been manifested in an
explosion of journal publications,
journals dedicated to this study
as well as the 2006 Nobel Prize
awarded to Fire and
Mello for their discovery
of the RNA interference pathway.
But surprisingly on the market,
there are only a handful
of nucleic acid therapeutics.
And these include
Macugen and Vitrovine.
Both of these drugs must
be directly injected
at the site of pathology, which
is in the vitreous of the eye.
And the backbone of
the nucleic acids
be modified to
enhance its stability.
So this exemplifies the kind of
difficulties associated with using
nucleic acids as
therapeutics, both regarding
its physiochemical properties
and biological properties.